Recombinant human RET/PTC1, the fusion protein [CCDC6 (1-101)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Catalog No. R02-19BG
|Catalog No.||Pack Size||Price (USD)|
RET/PTC1 is fused of RET and the activating CCDC6 gene by intrachromosomal paracentric inversions in chromo-some 10 (1). Likes RET/PTC3, it is the most frequent RET rearrangements in papillary thyroid carcinoma (PTC) (2), especially in radiation-induced tumours. The RET/PTC1 rearrangements may be a marker for later-occurring PTC of radiation-exposed children and adults (3). The RET/PTC rearrangements also have been shown in benign thyroid lesions, including Hashimoto's thyroiditis (HT).
CCDC6: H4, PTC, TPC RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC1
1. Grieco M. et al: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
2. Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002, 13:3-16.
3. Smida J. et al: Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer 1999, 80:32-38.
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
There are no related publications available for this product.
Cancer, Cell Cycle, Cellular Stress, Metabolic Disorder, Neurobiology